Navigation Links
PDL BioPharma Announces Second Quarter 2011 Financial Results
Date:7/27/2011

INCLINE VILLAGE, Nev., July 27, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2011.

Total revenues for the second quarter of 2011 were $122.1 million, compared to $120.3 million for the same period of 2010, a one percent year-over-year increase. Total revenues for the six months ended June 30, 2011, were $205.5 million, compared to $182.4 million for the same period of 2010. Included in results for the six months ended June 30, 2011, and not included in the same period in 2010, is a $10.0 million settlement payment from UCB Pharma S.A. resolving all legal disputes between the two companies. Excluding this one-time payment, revenue increased seven percent year over year for the six month period ended June 30, 2011.

Royalty revenues for the second quarter of 2011 are based on first quarter 2011 product sales by PDL's licensees. Revenue growth for the second quarter of 2011 over the same period in 2010 was primarily driven by increased first quarter 2011 sales by the Company's licensees of Herceptin®, which is marketed by Genentech and Roche; Lucentis®, which is marketed by Genentech and Novartis; and Tysabri®, which is marketed by Elan and Biogen Idec. Increases were offset, in part, by reduced royalties on sales of Avastin®. PDL received royalties for these product sales in the second quarter of 2011. The second quarter royalty payment received from Genentech included royalties generated on all worldwide sales.

Total general and administrative expenses for the second quarter of 2011 were $3.8 million, compared with $8.8 million for the same period of 2010. Total general and administrative expenses for the six months ended June 30, 2011, were $9.6 million, compared to $18.2 million for the same period in 2010. The decrease in the general and ad
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 The scientific team ... with one of the leading academics in the field of ... record holder in life extension for model animals - 10 ... of aging and age-related diseases, primarily, around the stability and ... just been published as "Stability analysis of a model gene ...
(Date:8/28/2015)... Aug. 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... completed the acquisition of leading OTC brands from GSK ... The transaction is a clear demonstration of Perrigo,s unique ... European distribution network spanning 36 countries.  ... commented, "We are excited to complete this transaction, ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Wash., April 23 Archus Orthopedics, Inc.,announced today ... implant,of its TFAS-C(TM) system, the newest addition to ... condition in which degenerative changes in,the facet joints ... in the legs. Traditionally, patients with moderate to,severe ...
... LOUISVILLE, Colo., April 23 Replidyne, Inc.,(Nasdaq: ... enrollment in a,placebo-controlled Phase III clinical trial testing ... chronic bronchitis,(AECB). Replidyne took this action to conserve ... strategic transactions and maintaining,its research programs., The ...
Cached Medicine Technology:First Human Implant of New Archus Orthopedics Facet Replacement System 2Replidyne Discontinues Phase III Trial 2Replidyne Discontinues Phase III Trial 3
(Date:8/30/2015)... , ... August 30, 2015 , ... ... joined the company as the new Global Communications Director for InHealth Media. ... experience having spent the last 16 years doing on-air television, producing shows, on ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... VA (PRWEB) , ... August 30, 2015 , ... ... Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... more than a simple digital handwritten signature. , Clinical trial sites ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... mesothelioma develops, may extend and improve the lives of patients, according to a ... Click here to read the full article. , The authors of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed ... of unique footage that users can shrink and stretch in the Final Cut Pro ... can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... Researchers at the University of Pittsburgh School of Medicine ... Institutes of Health, may be hot on the heels of ... way to not only protect healthy tissue from the toxic ... findings appear today in Science Translational Medicine . ...
... offspring thrive, study shows , WEDNESDAY, Oct. 21 (HealthDay News) ... reproduction via sex with a partner beats going it alone, evolutionarily ... do it one of two ways -- with a friend or ... the odds that the worms, children will live longer. , ...
... Speed Veterans, Appeals , WASHINGTON Oct. 21 ... of four new Veterans Law Judges to the Board of ... the number of cases being decided. , "Veterans have earned ... claims for benefits," Secretary Shinseki said. "This expansion of BVA ...
... a virtual subculture of "johns" who share information electronically ... to a new study co-authored by a Michigan State ... and Kristie Blevins of the University of North Carolina ... act alone and do not interact for fear of ...
... Van,s Gifts ... , ... -- For all those times when the words ,thank you, don,t live up to ... right message, at the right time and for the right price. , ,Van,s Gifts, Inc., a ...
... ... Washington, DC ... of the world,s vaccines and immunization launched by the World Bank, the United Nations Children,s ... Foundation strives to achieve. As a proud partner of the Measles Initiative and ...
Cached Medicine News:Health News:Pitt/NIH team find way to protect healthy cells from radiation damage 2Health News:Sex With a Partner Makes Evolutionary Sense: Study 2Health News:Secretary Announces Expansion of Veterans Appeals Board 2Health News:Internet fuels virtual subculture for sex trade, study finds 2Health News:Re-define 'Thank-You' With Style and Value From Van's Gifts 2Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation on the Launch of the State of the World's Vaccines and Immunization Report 2Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation on the Launch of the State of the World's Vaccines and Immunization Report 3
Custom-made chisels....
9 inch sharp bone hook with grip handle....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight, single action bone forceps to excise, trim and sculpt bone....
Medicine Products: